Nunn Jason Raleigh
Nunn Jason Raleigh's purchase track record
Nunn Jason Raleigh has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 10/9/2025 | ZBIO | $1.20M | -40.9% | -23.3% | +1.3% |
| 9/16/2024 | ZBIO | $15.00M | -51.2% | -53.1% | +0.8% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
ZBIO releases Phase 3 Obexelimab data, plans MS trial presentations. The company released new Phase 3 results for its Obexelimab program in IgG4‑related disease, which were presented at a recent international symposium. The data release coincided with a 5.1% share decline. Zenas also announced upcoming virtual presentations of Orelabrutinib data for multiple sclerosis at MSToronto2026 and a broader R&D webcast. Analyst HC Wainwright kept its $44 price target, reinforcing its view on the stock.
Transaction History
| ADXN | ▼ Sell | Other | 219,561 | $0 | 9/2/2026 | View on chart |
| ADXN | ▲ Buy | Grant | 219,561 | $0 | 9/2/2026 | View on chart |
| ZBIO | ▲ Buy | Open Market | 63,158 | $1.2M | 10/9/2025 | View on chart |
| ZBIO | ▼ Sell | Other | 1,505,388 | — | 9/16/2024 | View on chart |
| ZBIO | ▲ Buy | Open Market | 441,176 | $7.5M | 9/16/2024 | View on chart |
| ZBIO | ▼ Sell | Other | 669,061 | — | 9/16/2024 | View on chart |
| ZBIO | ▲ Buy | Open Market | 441,176 | $7.5M | 9/16/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 2, 2026
Addex Therapeutics Reports Q2 2026 Results and Management Changes
Addex Therapeutics announced executive management changes alongside its Q2 2026 earnings report. The company reported sales of $12,650, a decrease from $44,031 in the same period last year. Additionally, the company provided an update on its corporate status during the half-year results release.
Addex Therapeutics Reports Q2 2026 Results and Management Changes. Addex Therapeutics announced executive management changes alongside its Q2 2026 earnings report. The company reported sales of $12,650, a decrease from $44,031 in the same period last year. Additionally, the company provided an update on its corporate status during the half-year results release.